论文部分内容阅读
目的为评价重组人类促红细胞生成素(rhEPO)防治早产儿贫血的效果和安全性。方法将40例胎龄≤36周的早产儿随机分为治疗组和对照组各20例,治疗组予以国产rhEPO,750 IU/(kg.周)分3次皮下注射,用药6周;对照组未用rhEPO;两组早产儿均口服铁剂,3 mg/(kg.d)。结果显示治疗组用药后血清促红细胞生成素水平显著高于对照组(P<0.01);治疗组血红蛋白、红细胞压积比、网织红细胞均显著高于对照组(P<0.01);血清铁蛋白水平在用药后治疗组明显低于对照组(P<0.01);治疗组输血率较对照组明显减少(P<0.05);治疗组体重增长指标高于对照组(P<0.05)。结论国产rhEPO能有效防治早产儿贫血,且用药安全,无明显副作用。
Objective To evaluate the efficacy and safety of recombinant human erythropoietin (rhEPO) in the prevention and treatment of anemia in preterm infants. Methods Forty preterm infants with gestational age≤36weeks were randomly divided into treatment group (20 cases) and control group (n = 20). The patients in the treatment group were treated with rhEPO, and subcutaneously injected with 750 IU / (kg. Unused rhEPO; two groups of preterm children were oral iron, 3 mg / (kg.d). The results showed that the level of serum erythropoietin in the treatment group was significantly higher than that in the control group (P <0.01). The hemoglobin, hematocrit ratio and reticulocyte in the treatment group were significantly higher than those in the control group (P <0.01) (P <0.01). The blood transfusion rate of the treatment group was significantly lower than that of the control group (P <0.05). The body weight gain of the treatment group was higher than that of the control group (P <0.05). Conclusion Domestic rhEPO can effectively prevent and treat anemia in premature infants and is safe to use. There is no obvious side effect.